-  INCLUSION CRITERIA:

          -  Measurable metatstatic unresectable malignancy expressing G12V mutated KRAS as
             assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing
             or any other CLIA certified laboratory test on resected tissue. Patients shown to have
             tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes
             share complete amino acid homology with G12V mutated KRAS for their first 80
             N-terminal amino acids, completely encompassing the target epitope.

          -  Patients must be HLA-A*11:01 positive as confirmed by the NIH Department of
             Transfusion Medicine.

          -  Confirmation of the diagnosis of cancer by the Laboratory of Pathology of the NCI.

          -  Patients must:

          -  have previously received standard systemic therapy for their advanced cancer and have
             been either non-responders or have recurred. Specifically:

               -  For patients with metastatic colorectal cancer, they must have had at least two
                  systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab,
                  oxaliplatin and irinotecan (or similar agents) or have contraindications to
                  receiving those medications.

               -  Patients with pancreatic cancer must have received gemcitabine, 5FU, and
                  oxaliplatin (or similar agents), or have contraindications to receiving those
                  medications.

               -  Patients with non-small cell lung cancer (NSCLC) must have had appropriate
                  targeted therapy as indicated by abnormalities in ALK, EGFR or expression of PDL-
                  1. Other patients must have had platinum-based chemotherapy.

               -  Patients with ovarian cancer or prostate cancer must have had approved first line
                  chemotherapy

        OR

          -  have declined standard treatment

          -  Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
             asymptomatic are eligible. Lesions that have been treated with stereotactic
             radiosurgery must be clinically stable for 1 month after treatment for the patient to
             be eligible. Patients

        with surgically resected brain metastases are eligible.

          -  Age greater than or equal to 18 years and less than or equal to 70 years.

          -  Clinical performance status of ECOG 0 or 1

          -  Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for up to four months after treatment.

          -  Serology:

          -  Seronegative for HIV antibody. (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive can
             have decreased immune-competence and thus may be less responsive to the experimental
             treatment and more susceptible to its toxicities.)

          -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If
             hepatitis C antibody test is positive, then patient must be tested for the presence of
             antigen by RT-PCR and be HCV RNA negative.

          -  Hematology:

          -  ANC greater than or equal to 1000/mm^3 without the support of filgrastim

          -  WBC greater than or equal to 3000/mm^3

          -  Platelet count greater than or equal to 100,000/mm^3

          -  Hemoglobin > 8.0 g/dL

          -  Chemistry:

               -  Serum ALT/AST less than or equal to 5.0 x ULN

               -  Total bilirubin less tha or equal to 1.5 mg/dL, except in patients with Gilbert s
                  Syndrome who must have a total bilirubin less than or equal to 3.0 mg/dL.

          -  Patients must have either an eGFR > 60 mL/m (based on serum creatinine and lab
             nomogram) or a formal 6-24h CrCl > 60 mL/m.

          -  More than four weeks must have elapsed since completion of any prior systemic therapy
             and enrollment.

        Note: Patients may have undergone minor surgical procedures or limited field radiotherapy
        within the four weeks before enrollment, as long as related major organ toxicities have
        recovered to grade 1 or less.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

          -  Willing to sign a durable power of attorney.

          -  Subjects must be co-enrolled on NCI-SB cell harvest protocol 03-C-0277 (Cell Harvest
             and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Concurrent systemic steroid therapy.

          3. Active systemic infections requiring anti-infective treatment, coagulation disorders,
             or any other active or uncompensated major medical illnesses.

          4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          5. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          6. History of severe immediate hypersensitivity reaction to cyclophosphamide,
             aldesleukin, or fludarabine.

          7. History of coronary revascularization or ischemic symptoms

          8. Documented LVEF less than or equal to 45% tested in patients:

               -  Age greater than or equal to 65 years

               -  With clinically significant atrial and/or ventricular arrhythmias including but
                  not limited to: atrial fibrillation, ventricular tachycardia, second or third
                  degree heart block or have a history of ischemic heart disease and/or chest pain

          9. Documented FEV1 less than or equal to 50% predicted tested in patients with:

               -  A prolonged history of cigarette smoking (approximately 20 packs/year within the
                  past two years).

               -  Symptoms of respiratory dysfunction

         10. Patients who are receiving any other investigational agents